Autolus Therapeutics: Overlooked CAR-T Player With Key Catalysts Approaching

Summary

• Shares of AUTL have lost a third of their value over the past year.
• Sentiment in the autologous CAR-T space is improving as lead players successfully grow sales and scale up to meet demand.
• Obe-cel's lead opportunity in adult ALL is attractive relative to current enterprise value below $100 million.
• A confluence of data catalysts are coming 2H 22 and in 2023, including for AUTO4 in PTCL and obe-cel for additional indications of unmet need.
• AUTL is a Buy, in my view. Key risks include dilution in the near to medium term, competition in CD19 space and resources needed to successfully scale up to launch.
• Looking for a portfolio of ideas like this one? Members of ROTY Biotech Community get exclusive access to our model portfolio. Learn More »

Design Cells

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Disclaimer: Commentary presented is NOT individualized investment advice. Opinions offered here are NOT personalized recommendations. Readers are expected to do their own due diligence or consult an investment professional if needed prior to making trades. Strategies discussed should not be mistaken for recommendations, and past performance may not be indicative of future results. Although I do my best to present factual research, I do not in any way guarantee the accuracy of the information I post. I reserve the right to make investment decisions on behalf of myself and affiliates regarding any security without notification except where it is required by law. Keep in mind that any opinion or position disclosed on this platform is subject to change at any moment as the thesis evolves. Investing in common stock can result in partial or total loss of capital. In other words, readers are expected to form their own trading plan, do their own research and take responsibility for their own actions. If they are not able or willing to do so, better to buy index funds or find a thoroughly vetted fee-only financial advisor to handle your account.